ood morning, and welcome to the proverbial final Friday of summer. STAT reporter Rebecca Robbins here, filling in to bring your daily serving of headlines from the world of pharma. There’s just a few more hours of meetings, deadlines, and workaday responsibilities before the three-day weekend celebrating all that labor. Do try to relax, and be sure to stay safe, whatever it is you do. And while you’re still plugged in, do drop us a note if you hear anything interesting.
Indivior (LON:INDV) saw its stock price plummet after a U.S. court ruling opened the door to a generic rival to its treatment for opioid addiction, Reuters informs us. The company’s Suboxone film that dissolves under the tongue has an average market share of 60 percent in the U.S., but that could change if the Indian generics maker Dr. Reddy’s (RDY) comes in with a generic competitor.